Nutritional and dietary influences on attention deficit hyperactivity disorder

Natalie Sinn

Article first published online: 25 SEP 2008
DOI: 10.1111/j.1753-4887.2008.00107.x
© 2008 International Life Sciences Institute

Additional Information (Show All)

How to Cite
Abstract
Keywords: ADHD, food sensitivity; nutrition; omega-3 fatty acids; Pycnogenol

INTRODUCTION

A vast body of literature and research has been focused on attention deficit hyperactivity disorder (ADHD), which is the most prevalent childhood disorder, estimated to affect 5–10% of children depending largely on diagnostic criteria. Core symptoms associated with ADHD are developmentally inappropriate levels of hyperactivity, impulsivity, and inattention. ADHD has a high comorbidity rate with other mental health problems such as anxiety and mood disorders, including depression, suicidal ideation, and bipolar disorder. It is often associated with antisocial problems such as conduct disorder and oppositional defiant disorder. When combined with these problems, ADHD can lead to antisocial behavior, substance abuse, and borderline personality disorder in late adolescence and adulthood.

In addition, ADHD is associated with cognitive deficits; it has been estimated that a quarter of these children have a specific learning disability in math, reading, or spelling. Attention difficulties are associated with delays in general cognitive functioning, weak language skills, and poor adjustment in the classroom. The disruptive behavior, poor self-discipline, distractibility, and problems with response inhibition, self-regulation, and emotional control that are associated with ADHD can adversely impact families, relationships, social interactions, and children's self-esteem and school performance, presenting substantial personal, social, and economic burden for afflicted children, families, schools, and the broader community.

Prevalence of ADHD appears to be on the rise despite increased prescriptions of pharmaceutical medication, particularly methylphenidate and dextroamphetamine. Many parents are concerned about side effects of these medications, and a recent long-term follow-up of the Multimodal Treatment Study of Children with ADHD (MTA) study found that children in the pre-treatment who had been medicated with methylphenidate had slowed growth as well as increased risk of juvenile behavior and, possibly, substance abuse.

ADHD: CONTRIBUTING INFLUENCES

The etiology of ADHD is complex, and it is associated with both genetic and environmental factors. Studies of twins have provided strong evidence for a genetic component to the disorder, which, in combination with other biological factors, is likely to underlie the neurological deficits that are exacerbated over time by environmental influences. Psychophysiological research has identified neurological abnormalities, particularly in the frontal lobes, in children with ADHD compared with controls. Similarly, a number of studies have identified reduced blood flow to the frontal lobes in children with ADHD. This is consistent with hypotheses that symptoms of ADHD are related to abnormalities in noradrenergic and dopaminergic systems in the frontal lobes. The high comorbidity of ADHD with a variety of other psychopathologies suggests that these mental health problems share similar underlying neurological mechanisms. This notion is supported by the fact that children with ADHD often have family histories of neurodevelopmental and psychiatric disorders.

Biological influences that have been associated with ADHD via their impact on brain development and neurological functioning, include exposure to lead, mercury, and pesticides as well as prenatal exposure to tobacco. In many affected children, there are indications of suboptimal levels of various nutrients and evidence for behavioral reactions to certain foods and food additives. There is particularly compelling evidence that ADHD and other neurodevelopmental disorders such as dyspraxia, dyslexia, and autism may be associated with suboptimal levels of essential fatty acids. Therefore, it may be more prudent to address ADHD symptoms with a nutritional or dietary approach before prescribing medications. The present review evaluates the current state of evidence for the role of nutrients (following a brief overview of nutrition in brain development and function), Pycnogenol, and food sensitivities in ADHD.

NUTRITION AND ADHD

Nutrition and the brain

The brain's critical need for adequate nutrition is demonstrated by effects of malnutrition on the developing brain, including reduced DNA synthesis, cell division, myelination, glial cell proliferation, and dendritic branching. The pathological manifestation of malnutrition will depend on the stage of brain development at the time of nutritional insult. Effects of some nutrient deficiencies on development have become widely known and accepted; for instance, perinatal deficiencies in iodine—now considered the world's most preventable cause of mental retardation, folate-related to spinal bifida, and iron-related anemia. Severe deficiencies in omega-3 polyunsaturated fatty acids (PUFAs), particularly docosahexaenoic acid (DHA) can result in profound mental retardation associated with perisonal disorders.

Less extreme effects of suboptimal nutrient levels on brain development and ongoing function are not as well recognized.

Given the essentiality of an intricate interplay of macro- and micronutrients for optimal brain function, this could result in cognitive and behavioral problems for which the role of...
nutrition may be overlooked. Although the brain only accounts for 2-2.7% of body weight, it requires 25% of the body's glucose supply and 19% of the blood supply at rest; these requirements increase by 50% and 81%, respectively, in response to cerebral activity. Glucose is required for the brain's metabolic activities and is its primary source of energy. The brain has a limited capacity for storing glucose, however, and a reliable supply of blood and oxygen are therefore essential to maintaining cerebral blood flow and the integrity of the blood-brain barrier, including folate, pyridoxine, cobalamin, cholinergic, and omega-3 PUFAs. Neurotransmitters are also an integral component of the brain's communication system; various nutrients are required for monoamine metabolic pathways and act as essential cofactors for the enzymes involved in neurotransmitter synthesis.

**Zinc**

As well as playing important roles in immune function, growth, development, and reproduction, zinc is required for the developing brain. It plays numerous roles in ongoing brain function via protein binding, enzyme activity, and neurotransmission. As an essential cofactor for over 100 enzymes, zinc is required for the conversion of pyridoxine (B6) to its active form, which is needed to modulate the conversion of histamine to serotonin. Zinc is involved in the production and modulation of melatonin, which is required for dopamine metabolism and is a cofactor for delta-6 desaturase, which is involved in essential fatty acid conversion pathways.

A comprehensive review of the role of zinc in brain function and in ADHD is provided by Arnold. His review includes reports of zinc studies conducted in various parts of the world, which all found lower zinc levels in children with ADHD as well as correlations between lower zinc levels and severity of symptoms. One avenue of zinc depletion in these children may be via reactive processes in the hippocampus that results from oxidative stress. Twenty hyperactive males who reacted to the orange fruit-based treatment were challenged in a double-blind, placebo-controlled trial with 150 mg of the food additive. Following the challenge, serum zinc levels decreased and urine levels increased in the hyperactive group compared with controls, suggesting that metabolic wastage of zinc occurs under chemical stress. Behavioral and emotional symptoms also deteriorated in hyperactive children in association with changes in zinc levels.

Two clinical zinc supplementation trials have been conducted in children with ADHD. One controlled study found significant improvements in hyperactivity, impulsivity, and socialization scores, but not in attention. After 12 weeks of supplementation with 150 mg zinc per day in children with ADHD compared with controls, it should be noted that this is a particularly high dose of zinc, and there was a high dropout rate in the study (although it was significantly different between the active and placebo groups). The other study allocated 44 children who were diagnosed with ADHD to methylphenidate along with either 55 mg zinc sulfate or placebo over 6 weeks to investigate the benefits of zinc. Scores on parent and teacher rating scales for the zinc groups were improved in some hyperactive children, but these studies were significantly greater in the zinc group.

It is interesting to note that both zinc and free serum fatty acid levels were found to be lower in a group of 48 children with ADHD compared with 45 controls, and that these levels were strongly correlated in the ADHD group. In light of these studies and reports of other nutritional deficiencies in ADHD, the present author conducted a controlled trial (described below), which focused on omega-3 PUFAs and investigated the potential additive benefits of a multivitamin/mineral tablet in conjunction with the PUFAs supplement. Additional benefits were found with the MVM supplement, and the supplement contained <2 mg of zinc, which, in the studies above, is likely to have provided inconclusive results regarding potentially additive benefits of zinc combined with PUFAs.

**Iron**

Anemia from iron deficiency is estimated to affect 20-25% of infants, and many more are thought to suffer iron deficiencies without anemia, putting them at risk for delayed or impaired childhood development. Iron is important for the structure and function of the central nervous system and it plays a number of roles in neurotransmission. Iron deficiency has been associated with poor cognitive development and it has been proposed that iron deficiency may affect cognition and behavior via its role as a cofactor for tyrosine hydroxylase, the rate-limiting enzyme involved in dopamine synthesis.

Iron levels were found to be twice as low in 63 non-anemic children with ADHD compared to 27 controls with no other evidence of malnutrition; specifically, serum ferritin levels were abnormal (<30 ng/ml) in 84% of children with ADHD and 16% of controls (p < 0.001). Furthermore, low serum ferritin levels were correlated with more severe ADHD symptoms measured with Conners’ Parent Rating Scales (CPRS), particularly with cognitive problems and hyperactivity. A recent study also found low iron levels in 57 non-anemic children with ADHD, and these were correlated with hyperactivity scores on CPRS, although not with a range of cognitive assessments. It has been suggested that iron could play a role in ADHD due to its neuroprotective effects against lead exposure. Iron deficiency is also associated with restless legs syndrome, which is a common condition in children with ADHD symptoms, and may, therefore, account for greater variance in symptoms in this subgroup of children. Indeed, a recent study found that children with ADHD who suffered from restless legs had lower iron levels than those without restless legs.

An uncontrolled pilot study investigated the effects of iron supplementation on ADHD symptoms in 14 non-anemic 6-11-year-old boys. After 30 days of daily supplementation with 5 mg ferrous fumarate (active elemental iron, 0.05 mg/kg/day), blood samples showed increases in serum ferritin levels and significant decreases were found on parent ratings of symptoms on Conners' Rating Scales. However, these improvements were not correlated with increased iron levels and no significant improvements were found on teacher ratings. It was concluded that iron supplementation may not be effective in non-iron-deficient children and that it should be investigated in iron-deficient children with ADHD.

It is also possible that 30 days may not have been long enough to observe any effects. One report of a case study outlined the effects of iron supplementation on a 5-year-old boy with ADHD. This boy had an iron deficiency and also displayed sleep problems (delayed sleep onset and excessive morning sleep). After 4 months of iron supplementation, parents and teachers reported improvements in the child's symptoms, and marked improvements were reported after 9 months. He also showed improved quality of sleep.

These studies were followed up by a double-blind, placebo-controlled study with 45 non-anemic, 5-8-year-old iron-deficient children (serum ferritin levels <30 ng/ml) with ADHD. Following 12 weeks of supplementation with 45 mg ferrous fumarate per day or placebo, symptoms tended to improve in the treatment group on all ADHD scales and the improvements were significant on two outcome measures. Seventy-five percent of children in the treatment group had diagnosed or possible restless leg syndrome and this condition improved in 12 of those 14 children following iron supplementation. These improvements were not seen in the placebo group (p = 0.5). This study suggests indications that children with low iron levels who have both ADHD and restless legs may be more likely to benefit from iron supplementation.

**Magnesium**

Suboptimal magnesium (Mg) levels may impact brain function via a number of mechanisms including reduced energy metabolism, synaptic nerve cell signaling, and cerebral blood flow. It has also been suggested that its suppressive influence on the nervous system helps to regulate nervous and muscular excitability. Low Mg levels have been reported in children with ADHD. In 116 children with diagnosed ADHD, 95% were found to have Mg deficiency (77% in brain; 53% in blood serum), and those with this condition experienced significantly more frequent seizures in a control group. Magnesium levels were correlated highly with a child's degree of irritability. In 50 children aged 7-12 years with ADHD, Mg supplementation (200 mg/day) over 6 months resulted in significant reductions in hyperactivity and improved from irritability compared to a control group of 25 children with ADHD who were not treated with magnesium. Another open study also showed lower Mg levels in 30 of 52 hyperactive children compared with controls, and improvements in symptoms of hyperactivity following 1-6 months of supplementation with combined Mg and vitamin B6. A similar study by the same researchers 2 years later found lower Mg levels in 40 children with clinical symptoms of ADHD in 16 healthy controls. Decreased Mg levels were also associated with increased hyperactivity and sleep disturbance and poorer school attendance. After 2 months of Mg supplementation, 41 of the 40 children with ADHD, hyperactive symptoms were reduced and school performance improved. This work indicates the need for controlled studies in children with ADHD and magnesium deficiency.

**Omega-3 fatty acids**

Sixty percent of the dry weight of the brain is composed of fats, and the largest concentration of long-chain omega-3 PUFAs docosahexaenoic acid (DHA) in the body is found in the retina, brain, and nervous system. There is evidence that DHA is required for nerve cell myelination and is thus critical for neural transmission. Importantly, DHA levels in neural membranes vary according to dietary PUFAs intake. DHA precursor eicosapentaenoic acid (EPA) is also believed to have important functions in the brain, possibly via its role in synthesis of eicosanoids with anti-inflammatory, anti-thrombotic, and vasodilatory activity. Animal studies have associated omega-3 PUFAs with levels of neurotransmitters dopamine and serotonin. In the 1980s, researchers observed signs of fatty acid deficiency in hyperactive children; thereafter, a number of studies found lower omega-3 PUFAs levels in children with ADHD.
Nutritional and dietary influences on attention deficit hyperactivity disorder - Sinn - 2008 ...

compared with controls. Randomized controlled trials have found equivocal results, which may be explained by variations in selection criteria, sample size, dosage and nature of the omega-3 PUFA supplement and length of supplementation. One study performed in the United States supplemented 6–12-year-old medicated boys with a "pure" ADHD diagnosis (without comorbidities) with 345 mg of omega-3 PUFA daily for 16 weeks and found no significant improvements on outcome measures. Another study in the United States gave children aged 6–13 years with ADHD symptoms and skin and thirst problems 460 mg of DHA and 80 mg EPA along with 40 mg arachidonic acid (AA; omega-6 PUFA) daily over 4 months. Significant improvements were only found in outcome measures rated by parents and attention problems rated by teachers; importantly, the latter was correlated with increases in erythrocyte DHA levels. A study performed in Japan using both DHA and EPA found no significant treatment effects of fish oil (containing 3600 mg DHA and 700 mg EPA per week) on symptoms of ADHD in a 2-month, placebo-controlled, double-blind trial with 40 children aged 6–12 who were mostly drug-free (MADD). The placebo bread contained olive oil. Blood samples were not taken, so it is not clear whether this sample had a baseline deficiency in fatty acids. Given that the study was conducted in Japan, a country known to have high fish consumption, it is possible that they did not. It is also possible that 2 months may not have been a sufficient length of time for effects to become observable. Another pilot study in the United States supplemented 41 non-medicated children aged 6–12 years who had literacy problems (mainly dyslexia) and ADHD symptoms above the population average with 186 mg EPA and 480 mg DHA along with 42 mg AA per day for 12 weeks; the results showed improvements in literacy and in ADHD symptoms evaluated using Conners' Rating Scales.

Since these small trials, the results of two large, randomized, placebo-controlled, double-blind interventions have been published. The first was conducted in the United Kingdom with 117 non-medicated children aged 6–12 years with developmental coordination disorder; a third of these children had ADHD symptoms above the 50th percentile, placing them in the clinical range for a probable ADHD diagnosis. On average, these children were functioning a year behind their chronological age on reading and spelling. Following 3 months of daily supplementation with 552 mg EPA and 168 mg DHA with 60 mg gamma linolenic acid (GLA, omega-6 PUFA), children in the treatment group showed significant improvements in core ADHD symptoms, as rated by teachers on Conners' Rating Scales. The treatment group also increased their reading age by 9.5 months (compared to 3.3 months in the placebo group) and their spelling age by 6.6 months (compared to 1.2 months in the placebo group). A review of the above-mentioned studies was published following the latter trial.

The next study (conducted by the present author) investigated treatment in the same supplement in 132 non-medicated Australian children aged 7–12 years who had ADHD symptoms and dyslexia in the clinical range for a probable diagnosis. This study also investigated additive benefits of a multivitamin/mineral (MVM) supplement. There were no differences between the PUFA groups with and without the MVM supplement. However, both of the PUFA groups showed significant improvements compared to placebo in core ADHD symptoms, as rated by parents on Conners' Rating Scales over 16 weeks. Cognitive assessments found significant improvements in the children's ability to switch and control their attention, and in their vocabulary. Importantly, the latter improvements mediated parent-reported improvements in inattention, hyperactivity, and impulsivity. The effect sizes of the UK and Australian studies are similar to those reported in a meta-analysis of stimulant medication trials.

Our group is currently following up on these studies by comparing EPA-rich and DHA-rich oils, each providing 1 g omega-3 PUFA per day, on ADHD symptoms and literacy in children with ADHD and learning difficulties. The aim is to identify whether this subgroup with learning difficulties may be more likely to respond to omega-3 supplementation. We are also looking at the impact of dietary fats on school performance, and the impact of dietary fats on cognitive function. The effect sizes of the UK and Australian studies are similar to those reported in a meta-analysis of stimulant medication trials.

Pycnogenol and ADHD

Antioxidants are receiving growing interest for their potential to reduce oxidative stress in the brain, which may contribute to a variety of psychiatric disorders including autism and ADHD. Pycnogenol is the registered trademark for a potent antioxidant derived from maritime pine bark. It contains concentrated polyphenolic compounds, primarily procyanidins and phenolic acids (for a review of its pharmacology see Rohdewald). Pycnogenol may also increase nitric oxide production and has been reported to improve blood circulation. Therefore, it may assist with cerebral blood flow, which is also thought to be impaired in ADHD.

Several anecdotal reports indicate successful treatment of ADHD symptoms with Pycnogenol. In one case report, parents gave Pycnogenol to their 10-year-old boy with ADHD following unsuccessful response to stimulant medication. They noted significant improvements in target symptoms over 2 weeks. When they agreed to try him on stimulant medication again, he reportedly became significantly more hyperactive and impulsive and received numerous demerits at school. When Pycnogenol supplementation was reinstated, he again improved within 3 weeks.

Only two controlled studies with Pycnogenol have been conducted. One compared Pycnogenol with methylphenidate and placebo in a three-way crossover trial with 24 adults aged 24–50 years who met the criteria for ADHD. They were all given 1 mg/kg body weight Pycnogenol per day, methylphenidate (increased gradually from 10 mg to 45 mg per day) and placebo for 3 weeks, each separated by a 1-week washout. No significant improvements were observed in the methylphenidate or the Pycnogenol groups compared with placebo. It is possible that there was no treatment effect in this group or, alternatively, that 3 weeks was not long enough and/or the sample size was too small.

In the other study, 61 children aged 9–14 years with ADHD symptoms (diagnosed as hyperkinetic disorder (n = 44), hyperkinetic conduct disorder (n = 11), or ADD (n = 6)) were randomly allocated to receive 1 mg/kg body weight of Pycnogenol or placebo daily for 1 month and assessed again following an additional month of treatment washout. Significant improvements were observed in the treatment groups after 1 month, as measured by teacher ratings of hyperactivity and inattention, parent ratings of hyperactivity, and visual-motoric coordination and concentration. Symptoms tended to relapse following the 1-month washout. Importantly, biomarkers of oxidative damage decreased in the treatment group compared with placebo, and this was associated with improvement in symptoms. Further controlled studies are clearly warranted to investigate effects of Pycnogenol on ADHD symptoms in children.

A summary of double-blind, randomized, placebo-controlled nutritional interventions for ADHD, including Pycnogenol, is provided in Table 1.
Table 1. Summary of double-blind, randomized, placebo-controlled trials of nutrition in ADHD evaluating zinc, iron, omega-3 fatty acids, and Pycnogenol.

<table>
<thead>
<tr>
<th>Reference</th>
<th>Participants</th>
<th>Daily dose</th>
<th>Length of trial</th>
<th>Measures</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blicic et al. (2004)</td>
<td>N = 400; mean age 9.6; SD = 1.6 (78% boys); DSM-IV ADHD diagnosis, unmedicated</td>
<td>Zinc: 150 mg zinc</td>
<td>12 weeks</td>
<td>ADHD Scale (ADHDSS); ACTG; DuPaul Parent Ratings of ADHD</td>
<td>Treatment &gt; placebo: ADHDS; ADHDS-Subsocialization; ACTG-Hyperactivity; ACTG-Conduct; Treatment &gt; placebo on remaining measures</td>
</tr>
<tr>
<td>Akondzadeh et al. (2004)</td>
<td>N = 44; mean age 7.88; SD = 1.67 (69% boys); DSM-IV ADHD diagnosis, medicated</td>
<td>Zinc: 65 mg zinc</td>
<td>6 weeks</td>
<td>Parent and Teacher ADHD Rating Scales</td>
<td>Treatment &gt; placebo on both measures</td>
</tr>
<tr>
<td>Korotkova et al. (2008)</td>
<td>N = 23; 8-19 year old (78% boys); non-emic, iron-deficient (serum ferritin levels &lt; 30 mg/ml); DMS-IV criteria for ADHD; 16 had restless legs</td>
<td>Iron: 80 mg ferrous sulfate</td>
<td>12 weeks</td>
<td>CPRS; CTRS; ADHD rating scale; CGI-S; restless legs</td>
<td>Treatment &gt; placebo on ADHD rating scale and CGI-S; Treatment &gt; placebo on CPRS and CTRS; not significant; Restless legs improved in 12/14 in treatment group</td>
</tr>
<tr>
<td>Voigt et al. (2001)</td>
<td>N = 54; 6-12 year old (78% boys); idiopathic ADHD diagnosis, were being treated successfully with medication</td>
<td>n3 PUFAs: 345 mg</td>
<td>16 weeks</td>
<td>CPRS; BCBC; TOVA; CTR</td>
<td>Treatment &gt; placebo in all measures</td>
</tr>
<tr>
<td>Siewers et al. (2003)</td>
<td>N = 50; 6-17 year old (78% boys); ADHD diagnosis, high FA DADS; some on medication (equally allocated to conditions)</td>
<td>n3 and n6 PUFAs: 96 mg GLA, 40 mg AA, 80 mg EPA, 480 mg DHA, 24 mg E</td>
<td>16 weeks</td>
<td>DBD; ASQ; CPT; WJPEB-R; FADS</td>
<td>Treatment &gt; placebo: DBD-Compliance (parents); DBD-Attention (teachers); Other 14 outcome measures non-significant</td>
</tr>
<tr>
<td>Hineyama et al. (2004)</td>
<td>N = 42; 6-12 year old (90% boys); ADHD diagnosis, 15% medicated; 52% comorbid conditions</td>
<td>n3 PUFAs: 100 mg EPA, 514 mg DHA</td>
<td>8 weeks</td>
<td>DMS-IV ADHD; DTVP; STIM; CTR</td>
<td>Treatment &gt; placebo on all measures (except that placebo &gt; treatment on CPT and STM)</td>
</tr>
<tr>
<td>Richardson et al. (2002)</td>
<td>N = 20; 7-12 year old (62% boys); normal IQ; low reading ability; above-average ADHD scores on Conners' Index; no participants in treatment for ADHD</td>
<td>n3 and n6 PUFAs: 864 mg LA, 42 mg AA, 96 mg LNA, 186 mg EPA, 61 mg DHA, 50 mg VE</td>
<td>12 weeks</td>
<td>CPRS</td>
<td>Treatment &gt; placebo: CPRS; cognitive problems/feedback; anxiety; Conners' global index, DMS-Irregularity, DSM-Irregularity/Impulsivity, Conners' ADHD Index</td>
</tr>
<tr>
<td>Richardson et al. (2005)</td>
<td>N = 17; 5-12 year old (77% boys); developmental coordination disorder, 1/3 with ADHD symptoms in clinical range, not in treatment, IQ &gt; 70</td>
<td>n3 and n6 PUFAs: 60 mg AA, 10 mg GLA, 558 mg EPA, 174 mg DHA, 9.6 mg VE</td>
<td>12 weeks active vs placebo; one-way crossover to active treatment for 12 weeks</td>
<td>MABC; WORD; CTRs</td>
<td>Treatment &gt; placebo: WORD; oppositional behavior; cognitive problem/feedback; anxiety; attention, activity; perfectionism; social problems; Conners' Index; DMS-IV Irregularity, hyperactivity/impulsivity. Treatment &gt; placebo: MABC</td>
</tr>
<tr>
<td>Sinn et al. (2007)</td>
<td>N = 132 (questionnaire data available for 104); 7-12 years old (74% boys); ADHD symptoms in clinical range; unmedicated</td>
<td>n3 and n6 PUFAs: 60 mg AA, 10 mg GLA, 558 mg EPA, 174 mg DHA, 9.6 mg VE</td>
<td>15 weeks active vs placebo; one-way crossover to active treatment for 15 weeks</td>
<td>CPRS; CTRS</td>
<td>Treatment &gt; placebo CPRS; cognitive problem/feedback; hyperactivity; ADHD Index, restlessness/impulsivity, DMS-IV hyperactivity/impulsivity, oppositional. Treatment &gt; placebo on other subscales and CTRS</td>
</tr>
<tr>
<td>Tengenbaum et al. (2002)</td>
<td>N = 24; 24-62 years old (45% males); ADHD combined type</td>
<td>Pycnogenol: 1 mg/kg body weight</td>
<td>3 weeks on Pycnogenol; methylphenidate and placebo separated by 1-week wash-out</td>
<td>Barley's ADHD Scale; ADHA; DBD; IAI clinical interview; CTRs for AADD; BIS; Brown Add scales; CPT</td>
<td>Treatment &gt; placebo on all measures</td>
</tr>
<tr>
<td>Troubat et al. (2006)</td>
<td>N = 91; 6-14 year old (52% boys); hyperkinetic disorder, hyperkinetic conduct disorder, attention deficit without hyperactivity</td>
<td>Pycnogenol: 1 mg/kg body weight</td>
<td>1 month treatment of Pycnogenol</td>
<td>CAP; CTRS; CPRS; PDW</td>
<td>Treatment &gt; placebo: CAP Inattention and hyperactivity; CTRS maternal, CTRS hyperactivity; visual-motor co-ordination and concentration. Treatment &gt; placebo on remaining subscales</td>
</tr>
</tbody>
</table>

Positive treatment effects are presented in italic.

Abbreviations: n3 PUFA, omega-3 polyunsaturated fatty acids; n6 PUFA, omega-6 polyunsaturated fatty acids; ACTQ, Turkish adaptation of Conners' Teacher Rating Scales; ADHS, Attention Deficit Scales for Adults; CPT, Conners' Parent Rating Scales; ASQ, Conners' Abbreviated Symptom Questionnaires; BAI, Beck Anxiety Inventory; BDI, Beck Depression Inventory; BIS, Barratt Impulsiveness Scale; Brown ADD Scales; CAP, Child Attention Problems; Teacher rating scale; CBB, Child Behavior Checklist; CCR, Children's Color Trails Test; COG-I, Clinical Global Impression Severity; CPT, Continuous Performance Test; DBD, Disruptive Behavior Disorders rating scale; DTVP, Developmental Test of Visual Perception; FADS, fatty acid deficiency symptoms; MABC, Movement Assessment Battery for Children; Other, 2 questions assessing aggression and 2 questions assessing impatience; PDW, Prague Wechsler Intelligence Scale for Children (modified Wechsler Intelligence Scale for Children, WISC); RBP, Revised Behavior Problem Checklist; STM, short-term memory; TOVA, Test of Variables of Attention; V, vitamin E (tocopherol acetate); WJPEB, Woodcock-Johnson Psycho-Educational Battery; Revised; WORD, Wechsler Objective Reading Dimensions.

FOOD INTOLERANCE AND ADHD

In addition to nutritional influences, there is evidence that many of these children react to certain foods and/or food additives. Suggestions of links between diet and behavior go back to the 1950s, when they became well-known in the 1970s with the Feingold diet, which focused on eliminating naturally occurring salicylates, artificial food colors, artificial flavors, and the preservative butylated hydroxytoluene. 22

Behavioral reactions to food substances are associated with pharmacological rather than allergic mechanisms, although it is possible that these reactions coexist. 22 Underlying mechanisms for behavioral food reactions are not entirely clear. Increased motor activity was identified in neonatal rats following ingestion of red food color; 22 other animal studies linked reactions to the nervous system, e.g., similar hyperactive response was exhibited in dopamine depletion as well as administration of sulfite, an azo food dye metabolite, in developing rats. 22 A dose-dependent increase in red food color may increase the release of acetylcholine into neocortical synapses, and colors may affect uptake of neurotransmitters. 22 In support of animal studies, EEG readings were reported to normalize in nearly 50% of children (n = 20) with behavior disorders after starting an elimination diet. 23 Behavioral food reactions may be attributable to the presence of metals, including lead, mercury, and arsenic, in food coatings, which warrants investigation.


9/19/2011
Fong et al. reported that more than half of children who adhered to his elimination diet responded favorably and that many children’s behavioral symptoms reached the normal range. It has since been discovered, however, that many of the foods he excluded from the diet contained salicylates, and that many of these children also react to other food components such as food coloring. The complexity of dietary intervention, most notably the large variety of potentially suspect food substances and individual differences in the nature and dosage of the food intolerance, resulted in inconsistencies in subsequent research trials. Many of these studies also had methodological issues and did not involve the formulation of the intervention diet as well as the placebo diet and washout periods between them. Additionally, subsequent research has adapted to increasing knowledge on salicylates and potentially reactive food substances including amines.

Dietary interventions for ADHD and their inconsistent findings have generated a great deal of controversy, as have titles such as “Diet and child behavior problems: fact or fiction?” However, despite methodological difficulties of measuring dietary complexities and individual variation, a recent review cited eight controlled studies that found a significant improvement following a “few-food” (oligophenolic) diet compared with placebo or worsening of symptoms in placebo-controlled challenges of offending substances following an open challenge to identify the substance.

A meta-analysis of 15 double-blind, placebo-controlled trials focusing specifically on artificial food colors found that these food additives promoted hyperactive behavior in hyperactive children. Following this meta-analysis a randomized, double-blind, placebo-controlled, crossover challenge trial with 153 children aged 3 years and 144 aged 8 years from a general population of children reported significant effects of artificial colors and sodium benzoate preservative on hyperactive behavior. It should be noted that the food colorings and preservatives (placebo) were delivered in fruit juice containing salicylates, which could have confounded the effects for the more hyperactive children at risk for salicylate sensitivity. It is interesting that this study demonstrated hyperactive effects of food colorings on healthy children from a general population, thus expanding the effects of food colorings beyond children with sensitivities.

CONCLUSION

Research to date indicates that nutrition and diet may have a role in the hyperactivity and concentration/attention problems associated with ADHD in children. In children with suboptimal levels of iron, zinc, and magnesium, there is some support for improvements being achieved with supplementation of these nutrients. There are also indications that supplementation with Pyrogencin might assist with symptoms. However, more well-controlled clinical trials are required. The strongest support so far is for omega-3 PUFA and behavioral effects of food colorings. Research still needs to determine optimal levels of these nutrients for this group of children and markers of food sensitivity (currently requiring time-intensive dietary challenges) in order to inform clinical practice in the identification of potential deficiencies and/or behavioral food reactions. Suggestions that these children often react to histamine environmental substances such as petrol fumes, perfumes, fly sprays, and perfum, may also require further investigation.

There are clearly multiple influences on ADHD, including genetic and environmental (parental, social) factors. Whether these constitute different groups of children or whether there is a common underlying component to all of these remains to be determined. A recent study found lower omega-3 PUFA levels in 35 young adults with ADHD than in 112 controls, while iron, zinc, magnesium, or vitamin B6 were not reduced. However, since zinc is required for the metabolism of other nutrients, zinc deficiencies may contribute to suboptimal levels of nutrients such as omega-3 PUFA. In addition, a genetic problem with enzyme production or absorption of nutrients may predispose children to nutrient deficiencies and/or excessive overdosing, thus contributing concurrently to food sensitivities. Adverse genetic, environmental, and nutritional conditions may exacerbate psychosocial factors (e.g., it is easier to parent a child with an easygoing, undemanding personality). In order to provide optimal treatment for these children, all of these possibilities need to be explored in multidisciplinary, multistage, research models that take all potential factors into consideration.

Acknowledgment

Declaration of interest: NS is the current recipient of an Australian Research Council Fellowship, with contributions by Novosel Australia, for the 3-year project “Cognitive and behavioral benefits of omega-3 fatty acids across the lifespan.”

REFERENCES

Nutritional and dietary influences on attention deficit hyperactivity disorder - Sinn - 2008 ... Page 7 of 9


References


38  Konofal E, Cortese S. Lead and neuroprotection by iron in ADHD. Environ Health Perspect. 2007;115:A398–A400.


Abstract | PDF(412K) | References


